BITE
LIVE

Serial Number

78040636

Owner

Micromet AG

Attorney

Elsa D. Lemoine

Filing Date

Dec 26, 2000

Add to watchlist:

No watchlists yet
View on USPTO

BITE Trademark

Serial Number: 78040636 • Registration: 3068856

BITE is a trademark filed by Micromet AG on December 26, 2000. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Micromet AG (7 trademarks)

Staffelseestr. 2

Entity Type: 09

Amgen Research (Munich) GmbH (2 trademarks)

Munich 81477 , DE

Entity Type: 16

Trademark Details

Filing Date

December 26, 2000

Registration Date

March 14, 2006

Published for Opposition

September 9, 2003

Goods & Services

[ Medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, in the form of intravenous, sub-cutaneous, intra-peritoneal, intra-muscular and aerosol therapies ]

[ Human and veterinary services, namely, licensing of medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases; licensing of technology for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with FACS or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells ]

Medical services; laboratory research in the field of polypeptides, particularly antibodies and antibody derivatives; human and veterinary services, namely, product development, in the field of medicaments, namely, polypeptides, particularly antibodies and antibody derivatives, for use in the treatment of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host disease, transplant rejection, coronary heart diseases and minimal residual diseases; product development, in the field of diagnostic and testing apparatus and instruments for the identification of tumorous diseases, allergies, autoimmunity, inflammation, infectious diseases, osteoporosis, graft versus host diseases, transplant rejection, coronary heart diseases, and minimal residual diseases, and for the identification of expressed genes, particularly of abnormal expressed genes, for the analysis and identification of the gene expression pattern and eukaryotic cells, particularly of single cells and cell culture lines, particularly of mammalian and human cells, particularly of cells of microscopic small biopsies of animal and human tissues, of cells out of tissue samples prepared with laser, of cells isolated with FACS or with receptor to ligand binding, of chemical fixed tissue, of micrometastatic cells, of bone marrow cells, of samples of body fluids, particularly from liquor, blood, lymph, urine or bowel movement, of stem cells, cloned single cells or differentiated stages from specific cells

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Mar 14, 2025 REM2
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 29, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 29, 2022 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Apr 29, 2022 EWOR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 29, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 29, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 29, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 29, 2022 COAR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 7, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 7, 2019 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2018 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 28, 2016 NAS8
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 28, 2016 RNL1
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Jun 28, 2016 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Jun 28, 2016 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 28, 2016 APRE
TEAS SECTION 8 & 9 RECEIVED
Apr 8, 2016 E89R
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 23, 2016 ASGN
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Mar 14, 2015 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 2, 2012 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 1, 2012 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 31, 2012 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 1, 2012 E815
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 18, 2011 TCCA
REGISTERED-PRINCIPAL REGISTER
Mar 14, 2006 R.PR
LAW OFFICE REGISTRATION REVIEW COMPLETED
Feb 1, 2006 REGV
ASSIGNED TO LIE
Feb 1, 2006 ALIE
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 17, 2006 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 27, 2005 SUPC
PAPER RECEIVED
Dec 5, 2005 MAIL
USE AMENDMENT FILED
Dec 2, 2005 IUAF
SOU EXTENSION 3 GRANTED
Jun 3, 2005 EX3G
SOU EXTENSION 3 FILED
May 19, 2005 EXT3
SOU TEAS EXTENSION RECEIVED
May 19, 2005 EEXT
SOU EXTENSION 2 GRANTED
Dec 8, 2004 EX2G
SOU EXTENSION 2 FILED
Nov 29, 2004 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 29, 2004 EEXT
SOU EXTENSION 1 GRANTED
May 28, 2004 EX1G
CASE FILE IN TICRS
May 26, 2004 CFIT
SOU EXTENSION 1 FILED
May 19, 2004 EXT1
SOU TEAS EXTENSION RECEIVED
May 19, 2004 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Dec 2, 2003 NOAM
PAPER RECEIVED
Sep 29, 2003 MAIL
PUBLISHED FOR OPPOSITION
Sep 9, 2003 PUBO
NOTICE OF PUBLICATION
Aug 20, 2003 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2003 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 22, 2003 CRFA
PAPER RECEIVED
May 22, 2003 MAIL
NON-FINAL ACTION MAILED
Jan 6, 2003 CNRT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2002 CRFA
PAPER RECEIVED
Oct 21, 2002 MAIL
NON-FINAL ACTION MAILED
Jun 26, 2002 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jun 9, 2002 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2002 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 10, 2002 ZZZX
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2002 CRFA
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 5, 2002 CNSA
EXAMINERS AMENDMENT MAILED
Feb 4, 2002 CNEA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 29, 2001 CRFA
NON-FINAL ACTION MAILED
Jun 6, 2001 CNRT
ASSIGNED TO EXAMINER
May 17, 2001 DOCK